This brand name is authorized in Nigeria.
The drug LICAFUR contains one active pharmaceutical ingredient (API):
1
|
UNII
Z49QDT0J8Z - CEFUROXIME AXETIL
|
|
Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| A4-9912 | Suspension | LICAFUR SUSPENSION SUSP 125 mg/5 mL 100ML | LICAFUR SUSPENSION CEUFUROXIME AXETIL CEFUROXIME AXETIL 125MG/5ML A4-9912 Drugs ANTIINFECTIVES FOR SYSTEMIC USE Nigerian Products 100ML POM 1 24/10/2022 ZOLON HEALTHCARE LIMITED, BLOCK A, ASWANI MARKET ROAD, ISOLO LAGOS 17391531 fuche-nwachi@emzorpharma.com BAROQUE PHARMACEUTICALS PVT. LTD, 192/2 & 3, 190/1 & 202/9, SOKHADA - 388 620, TAL. KHAMBHAT, DIST. ANAND (GUJARAT, INDIA, India | 27/07/2023 |
| B4-0098 | Tablet | LICAFUR 500MG TABLET TAB 500 mg 1 X 10 | 34 CMS-PP-289972 LICAFUR 500MG TABLET CEUFUROXIME AXETIL CEFUROXIME AXETIL 500MG B4-0098 Drugs ANTIINFECTIVES FOR SYSTEMIC USE Nigerian Products 1x10 POM 1 10/24/2022 ZOLON HEALTHCARE LIMITED, BLOCK A, ASWANI MARKET ROAD, ISOLO LAGOS 17391531 fuche-nwachi@emzorpharma.com BAROQUE PHARMACEUTICALS PVT. LTD, 192/2 & 3, 190/1 & 202/9, SOKHADA - 388 620, TAL. KHAMBHAT, DIST. ANAND (GUJARAT, INDIA, India | 06/07/2023 |
| B4-0099 | Tablet | LICAFUR 250MG TABLET TAB 250 mg 1 X 10 | 33 CMS-PP-289965 LICAFUR 250MG TABLET CEUFUROXIME AXETIL CEFUROXIME AXETIL 250MG TABLET B4-0099 Drugs ANTIINFECTIVES FOR SYSTEMIC USE Nigerian Products 1x10 POM 1 10/24/2022 ZOLON HEALTHCARE LIMITED, BLOCK A, ASWANI MARKET ROAD, ISOLO LAGOS 17391531 fuche-nwachi@emzorpharma.com BAROQUE PHARMACEUTICALS PVT, LTD., , 192/2/3, SOKHADA-388620, TA. KHAMBHAT DISTRICT. ANAND, GUJARAT STATE, INDIA., India | 06/07/2023 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J01DC02 | Cefuroxime | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | A4-9912, B4-0098, B4-0099 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.